首页 | 本学科首页   官方微博 | 高级检索  
     


Autophagy and polyglutamine diseases
Authors:Jimenez-Sanchez Maria  Thomson Frances  Zavodszky Eszter  Rubinsztein David C
Affiliation:Department of Medical Genetics, Cambridge Institute for Medical Research, Addenbrooke's Hospital, University of Cambridge, Hills Road, Cambridge CB2 0XY, UK.
Abstract:In polyglutamine diseases, an abnormally elongated polyglutamine tract results in protein misfolding and accumulation of intracellular aggregates. The length of the polyglutamine expansion correlates with the tendency of the mutant protein to aggregate, as well as with neuronal toxicity and earlier disease onset. Although currently there is no effective cure to prevent or slow down the progression of these neurodegenerative disorders, increasing the clearance of mutant proteins has been proposed as a potential therapeutic approach. The ubiquitin-proteasome system and autophagy are the two main degradative pathways responsible for eliminating misfolded and unnecessary proteins in the cell. We will review some of the studies that have proposed autophagy as a strategy to reduce the accumulation of polyglutamine-expanded protein aggregates and protect against mutant protein neurotoxicity. We will also discuss some of the currently known mechanisms that induce autophagy, which may be beneficial for the treatment of these and other neurodegenerative disorders.
Keywords:HD, Huntington's disease   SCA, spinocerebellar ataxia   DRPLA, Denatorubral-pallidoluysian atrophy   SBMA, spinal and bulbar muscular atropy   Htt, Huntingtin   UPS, ubiquitin–proteasome system   HDL-2, Huntington's disease-like 2   IBs, inclusion bodies   RNAi, RNA interference   Atg, autophagy-related genes   ER, endoplasmic reticulum   PI3K, phosphatidylinositol 3-kinase   JNK1, c-Jun N-terminal protein kinase 1   PE, phosphatidylethanolamine   SNAREs, soluble N-ethylmaleimide-sensitive factor attachment protein receptors   mTOR, mammalian target of rapamycin   PI-3-P, phosphatidylinositol-3-phosphate   ROS, reactive oxygen species   IP3, inositol-1,4,5-triphosphate   IP3R, IP3 receptors   cAMP, cyclic AMP   IMPase, inositol monophosphatase   GSK3β, glycogen synthase kinase-3 β   I1R, imidazoline-1-receptor   SMERs, small molecule enhancers of rapamycin   SMIRs, small molecule inhibitors of rapamycin
本文献已被 ScienceDirect PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号